|
RBM39 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.92168503332368E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.59779983583053E-10 |
| Normal-vs-Stage2 |
2.67390554142821E-11 |
| Normal-vs-Stage3 |
1.32449606837781E-13 |
| Normal-vs-Stage4 |
5.03279999897188E-08 |
| Stage1-vs-Stage2 |
1.413600E-02 |
| Stage1-vs-Stage3 |
4.955300E-03 |
| Stage1-vs-Stage4 |
3.014800E-01 |
| Stage2-vs-Stage3 |
7.288200E-01 |
| Stage2-vs-Stage4 |
2.761600E-01 |
| Stage3-vs-Stage4 |
3.405800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.87481191366624E-13 |
| Normal-vs-AfricanAmerican |
1.418740E-04 |
| Normal-vs-Asian |
3.7962000000058E-05 |
| Caucasian-vs-AfricanAmerican |
3.552800E-01 |
| Caucasian-vs-Asian |
7.794200E-02 |
| AfricanAmerican-vs-Asian |
7.250600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.3462998210988E-10 |
| Normal-vs-Female |
2.31514807325084E-12 |
| Male-vs-Female |
8.106800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.4505000512961E-09 |
| Normal-vs-Age(41-60Yrs) |
5.93769478030026E-12 |
| Normal-vs-Age(61-80Yrs) |
5.46007683510652E-12 |
| Normal-vs-Age(81-100Yrs) |
1.32499999971891E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.863600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.359200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.275300E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.274800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.157600E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.840400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.027950E-04 |
| Classical-VS-Follicular |
5.908200E-02 |
| Classical-VS-Other |
4.827800E-01 |
| Classical-VS-Normal |
1.10130016217624E-10 |
| Tall-VS-Follicular |
9.602400E-02 |
| Tall-VS-Other |
1.028470E-02 |
| Tall-VS-Normal |
2.0575763315378E-12 |
| Follicular-VS-Other |
2.513800E-01 |
| Follicular-VS-Normal |
2.70080002806594E-09 |
| Other-VS-Normal |
6.481900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.28008714739281E-13 |
| Normal-vs-N1 |
7.94170000000261E-05 |
| N0-vs-N1 |
1.141240E-01 |
|
|
